

VYKOURA™

(leucovorin calcium) injection

BILLING AND CODING GUIDE

If you have additional billing and coding questions, please call your Field Reimbursement Manager or AVYXASSIST® at 866-939-8927. Our Patient Access Specialists are available to assist Monday through Friday, 8 AM to 8 PM ET.



TABLE OF CONTENTS

Indications and Important Safety Information	3, 17-18
VYKOURA™ Ordering Information	4
AVYXASSIST® Patient Support Program	5
VYKOURA Billing and Coding Information	6
NDCs	6
HCPCS Code	6
Modifiers	7
CPT Drug Administration Codes	8
Revenue Codes	8
Place of Service (POS) Codes	9
ICD-10-CM Diagnosis Coding	9
ICD Diagnosis Codes by Indication	10-12
Sample UB-04 / CMS 1450 Claim Form	13-14
Sample CMS 1500 Claim Form	15-16
Important Safety Information (Continued)	17-18
Notes	19

The contents herein provide general coverage, coding, and payment information about VYKOURA. The information within this guide was obtained from third-party sources and is made available for reference only. It is not exhaustive, is subject to change, and does not constitute billing, coding, or legal advice. Healthcare professionals are responsible for determining which code(s), charge(s), or modifier(s), if any, appropriately reflect a service or diagnosis. It is the healthcare professional's responsibility to determine medical necessity and provide adequate documentation. AVYXA Pharma, LLC does not guarantee coverage or payment. Payment and coverage vary by payer. Questions about coding, coverage, and payment may be directed to the applicable third-party payer, reimbursement specialist, and/or legal counsel.

INDICATIONS AND IMPORTANT SAFETY INFORMATION

INDICATIONS

VYKOURA™ (leucovorin calcium) injection is indicated for:

- Rescue after high-dose methotrexate (MTX) therapy in adult and pediatric patients.
- Reducing the toxicity of:
 - Methotrexate in adult and pediatric patients with impaired methotrexate elimination or
 - Folic acid antagonists or dihydrofolate reductase (DHFR) inhibitors following an overdose in adult and pediatric patients.
- Treatment of megaloblastic anemias due to folic acid deficiency in adult and pediatric patients when oral therapy is not feasible.
- Treatment of patients with metastatic colorectal cancer in combination with fluorouracil.

Limitations of Use

VYKOURA is not indicated for pernicious anemia and megaloblastic anemia secondary to the lack of vitamin B₁₂, because of the risk of progression of neurologic manifestations despite hematologic remission.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

VYKOURA is contraindicated in patients who have had a severe hypersensitivity reaction to leucovorin (folinic acid), levoleucovorin, or folic acid. Reactions have included anaphylactic reactions.

WARNINGS AND PRECAUTIONS

Hypersensitivity

Hypersensitivity reactions, including anaphylactic reactions and urticaria, have been reported following the administration of leucovorin. VYKOURA is contraindicated in patients who have had a severe hypersensitivity reaction to leucovorin, levoleucovorin, or folic acid. Withhold or permanently discontinue VYKOURA based on the severity of hypersensitivity.

Hypercalcemia

Because of the calcium content of the VYKOURA, do not administer more than 160 mg of VYKOURA intravenously per minute.

Risk of Administration Errors

In the treatment of accidental overdoses of intrathecally administered folic acid antagonists, do not administer VYKOURA intrathecally. VYKOURA MAY BE HARMFUL OR FATAL IF GIVEN INTRATHECALLY.

ADVERSE REACTIONS

The most common adverse reactions (≥20%) in patients receiving high-dose methotrexate therapy with leucovorin rescue are stomatitis and vomiting.

The most common adverse reactions (>50%) in patients receiving leucovorin in combination with fluorouracil for metastatic colorectal cancer are stomatitis, diarrhea, and nausea.

VYKOURA™

(leucovorin calcium) injection

Ordering Information

To order VYKOURA (leucovorin calcium) injection, please contact one of the authorized specialty distributors below:



50 mg/5 mL
NDC: 83831-0147-05



350 mg/35 mL
NDC: 83831-0148-35



500 mg/50 mL
NDC: 83831-0149-50



CardinalHealth

Cencora

McKesson

Highlights¹

- Aqueous formulation with enhanced solubility to avoid crystallization
 - Indicated for both intravenous (IV) and intramuscular (IM) administration
 - No reconstitution required prior to administration
 - Ready-to-use liquid formulation

UNIQUE
J-CODE

J0644

Effective October 1, 2026

AVYXASSIST®

Simplifying patient access, providing comprehensive support

AVYXASSIST can offer support to qualifying patients in need. The program provides the following services.*

- Benefit verification
- Prior authorization assistance
- Appeals support
- Claims support
- Referrals to 501(c)(3) foundations
- Free product assistance
- Bridge supply
- Product replacement
- Copay assistance

*For eligibility requirements, please contact a Patient Access Specialist. Terms and conditions apply.

To enroll, please choose one of the following options.

Call 866-939-8927
Monday through Friday
8 AM to 8 PM ET



CALL NOW

Click on the link
below to begin
online enrollment



ENROLL
NOW

Download, print, and fax
a completed enrollment
form to 833-852-3420



DOWNLOAD
NOW

Commercially eligible patients
prescribed an **AVYXA Pharma,
LLC product** may pay as little as

\$0 per dose*

AVYXASSIST™

ELIGIBLE PATIENTS
MAY PAY AS
LITTLE AS \$0

BIN 025706
PCN IFX
GROUP # 00000000
MEMBER # 0000000000



Patients with questions, please call 866-939-8927

Our dedicated AVYXASSIST Patient Access Specialists work collaboratively with you to explore tailored affordability solutions. AVYXA Pharma, LLC aims to facilitate financial accessibility for eligible patients in need.



ENROLL
NOW

Copay Program Details for Eligible Patients

In some cases, the patient out-of-pocket cost for their AVYXA Pharma, LLC product could be as low as \$0.*

- Up to \$25,000 per patient, per drug.

*Please visit avyxassist.com/copay-assistance-program to see full Terms and Conditions.

Additional Assistance

Patients without insurance or who do not qualify for copay assistance through AVYXASSIST may qualify for free product assistance. Call an AVYXASSIST Patient Access Specialist to learn more.

Call 866-939-8927 or Fax 833-852-3420 | Monday through Friday, 8:00 AM to 8:00 PM ET

Please see Important Safety Information on pages 3 and 17-18 and full [Prescribing Information](#) for VYKOURA™.

VYKOURA™ Billing and Coding Information

The information provided is for informational purposes only and represents no statement, promise, or guarantee by AVYXA Pharma, LLC concerning reimbursement, payment, or charges. The information provided is not intended to increase or maximize reimbursement by any payer. Healthcare professionals are responsible for selecting appropriate codes used to file a claim. Codes should be based on the patient's diagnosis and the items and services furnished by the healthcare professional. All codes should be verified between the healthcare professional and the payer. AVYXA Pharma, LLC does not recommend using any particular diagnosis code in billing situations for VYKOURA (leucovorin calcium) injection. The codes below are for reference only; coding as submitted is the sole responsibility of the prescribing physician.

NDCs for VYKOURA Injection

National Drug Codes (NDC) are unique product identifiers used for drugs and biologicals. The Centers for Medicare & Medicaid Services (CMS) and private payers often require an NDC as part of the billing claim form. If the NDC Package code is less than 11 digits, the code must be padded with leading zeros, as shown below.²

NDC ¹	Strength	Vial Size	NDC Unit
83831-0147-05	50 mg/5 mL (10 mg/mL)	Single-dose vial	mL
83831-0148-35	350 mg/35 mL (10 mg/mL)	Single-dose vial	mL
83831-0149-50	500 mg/50 mL (10 mg/mL)	Single-dose vial	mL

Note: NDC Unit = mL to maintain consistency with Avyxa's standardized quick-reference tables for liquid dosage forms.

HCPCS Code³

HCPCS Level II codes are used to identify most drugs and biologics administered in an office setting. Correct coding requires reporting the most specific code to describe the service accurately.

VYKOURA Injection J-Code ⁴	Description
J0644	Injection, leucovorin calcium (avyxa), 1 mg

Contact your Account Manager to connect with a Field Reimbursement Manager for the latest payer coverage for patients and assistance with billing and coding.

Modifiers

A medical coding modifier is two characters (letters or numbers) appended to a CPT or HCPCS Level II code. Modifiers provide additional information about the medical procedure or service without changing the definition of the code. Using modifiers allows healthcare providers to specify specific circumstances, such as the route of administration, wasted product, and other relevant details.⁷

Drug Waste Modifiers ⁸	
Modifier	Description
JW	Drug amount discarded/not administered to patient
JZ	Zero drug amount discarded/not administered to patient

VYKOURA injection is packaged as a single-dose vial.¹ Medicare will pay for drug waste on single-use items that are medically necessary and appropriately documented in the patient's medical record. Medicare requires discarded drugs to be reported with the -JW modifier on a separate line; if there is no waste, VYKOURA injection must be billed on one line with the modifier -JZ.⁸

340B Drug Pricing Modifier ⁹	
Modifier	Description
TB	Drug or biological acquired with 340b drug pricing program discount, reported for informational purpose

The "TB" modifier is used for informational purposes to identify drugs purchased through the 340B program. This enables CMS to accurately implement the Part B inflation rebate program established by the Inflation Reduction Act of 2022, as 340B drugs are excluded from the inflation rebate calculation.⁹

CPT Drug Administration Codes

CPT codes bill for drug administration services in the physician's office and other outpatient settings. Administration of VYKOURA™ varies by indication and usage. Please code based on the start and stop times listed in the patient's medical chart.¹⁰

CPT Code ⁹	Description
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); initial, up to 1 hour
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); each additional hour (List separately in addition to code for primary procedure)
96367	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure)
96368	Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); concurrent infusion (List separately in addition to code for primary procedure)
96372	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular
96374	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous push, single or initial substance/drug
96375	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of a new substance/drug (List separately in addition to code for primary procedure)
96376	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential intravenous push of the same substance/drug provided in a facility (List separately in addition to code for primary procedure)
96416	Chemotherapy administration, intravenous infusion technique; initiation of prolonged chemotherapy infusion (more than 8 hours), requiring use of a portable or implantable pump

CPT codes, descriptions, and other data are copyright 2025 American Medical Association. All Rights Reserved. Applicable FARS/ HHSARS apply. Fee schedules, relative value units, conversion factors, and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

Most Commonly Used Codes: CPT **96365** (initial IV infusion, up to 1 hour) and **96367** (additional sequential infusion of a new drug/substance, up to 1 hour) are most frequently used for **VYKOURA intravenous administration** based on treatment protocols.

Revenue Codes¹²

Claim Item	Revenue Code	Description
VYKOURA Injection	0636	Drugs requiring detailed coding
Drug Administration	0260	IV Therapy – General
	0261	IV Therapy – Infusion Pump
Pharmacy Services	0250	Pharmacy - General

Place of Service (POS) Codes¹³

Place of service (POS) Codes are used on professional claims to specify the entity where service(s) are rendered.

Place of Service	Code	Description
Physician Office	11	Location, other than a hospital, skilled nursing facility (SNF), military treatment facility, community health center, State or local public health clinic, or intermediate care facility (ICF), where the health professional routinely provides health examinations, diagnosis, and treatment of illness or injury on an ambulatory basis.
Off-Campus Outpatient Hospital	19	A portion of an off-campus hospital provider-based department which provides diagnostic, therapeutic (both surgical and nonsurgical), and rehabilitation services to sick or injured persons who do not require hospitalization or institutionalization.
On-Campus Outpatient Hospital	22	A portion of a hospital's main campus, which provides diagnostic, therapeutic (both surgical and nonsurgical), and rehabilitation services to sick or injured persons who do not require hospitalization or institutionalization.

ICD-10-CM Diagnosis Coding

VYKOURA™ (leucovorin calcium) injection is indicated for¹:

- Rescue after high-dose methotrexate (MTX) therapy in adult and pediatric patients.
- Reducing the toxicity of:
 - Methotrexate in adult and pediatric patients with impaired methotrexate elimination or
 - Folic acid antagonists or dihydrofolate reductase (DHFR) inhibitors following an overdose in adult and pediatric patients.
- Treatment of megaloblastic anemias due to folic acid deficiency in adult and pediatric patients when oral therapy is not feasible.
- Treatment of patients with metastatic colorectal cancer in combination with fluorouracil.

International Classification of Disease, 10th Edition, Clinical Modification Codes for VYKOURA Injection¹⁴

Indication	ICD-10-CM Codes
Colorectal Cancer	C18.0; C18.1; C18.2; C18.3; C18.4; C18.5; C18.6; C18.7; C18.8; C18.9; C19; C20; C21.8
Osteosarcoma	C40.00; C40.01; C40.02; C40.10; C40.11; C40.12; C40.20; C40.21; C40.22; C40.30; C40.31; C40.32; C40.80; C40.81; C40.82; C40.90; C40.91; C40.92; C41.0; C41.1; C41.2; C41.3; C41.4; C41.9
Folate Deficiency Anemia	D52.0; D52.1; D52.8; D52.9
Poisoning by Antineoplastic and Immunosuppressive Drugs	T45.1X1A; T45.1X1D; T45.1X1S
Adverse Effect of Antineoplastic and Immunosuppressive Drugs	T45.1X5A; T45.1X5D; T45.1X5S
Encounter for Antineoplastic Chemotherapy	Z51.11
Long Term Use of Antimetabolites (includes 5-fluorouracil and methotrexate)	Z79.631

VYKOURA™ injection Billing and Coding Information: ICD Diagnosis Codes by Indication

ICD-10-CM coding for VYKOURA injection varies by payer. Please check with each payer to ascertain the best coding for VYKOURA injection according to their policy.

Colorectal Cancer: ICD-10-CM Diagnosis Coding ¹⁴	
ICD-10 Code	Descriptor
C18.0	Malignant neoplasm of cecum
C18.1	Malignant neoplasm of appendix
C18.2	Malignant neoplasm of ascending colon
C18.3	Malignant neoplasm of hepatic flexure
C18.4	Malignant neoplasm of transverse colon
C18.5	Malignant neoplasm of splenic flexure
C18.6	Malignant neoplasm of descending colon
C18.7	Malignant neoplasm of sigmoid colon
C18.8	Malignant neoplasm of overlapping sites of colon
C18.9	Malignant neoplasm of colon, unspecified
C19	Malignant neoplasm of rectosigmoid junction
C20	Malignant neoplasm of rectum
C21.8	Malignant neoplasm of overlapping sites of rectum, anus and anal canal

Osteosarcoma: ICD-10-CM Diagnosis Coding ¹⁴	
ICD-10 Code	Descriptor
C40.00	Malignant neoplasm of scapula and long bones of unspecified upper limb
C40.01	Malignant neoplasm of scapula and long bones of right upper limb
C40.02	Malignant neoplasm of scapula and long bones of left upper limb
C40.10	Malignant neoplasm of short bones of unspecified upper limb
C40.11	Malignant neoplasm of short bones of right upper limb
C40.12	Malignant neoplasm of short bones of left upper limb
C40.20	Malignant neoplasm of long bones of unspecified lower limb
C40.21	Malignant neoplasm of long bones of right lower limb
C40.22	Malignant neoplasm of long bones of left lower limb
C40.30	Malignant neoplasm of short bones of unspecified lower limb

C40.31	Malignant neoplasm of short bones of right lower limb
C40.32	Malignant neoplasm of short bones of left lower limb
C40.80	Malignant neoplasm of overlapping sites of bone and articular cartilage of unspecified limb
C40.81	Malignant neoplasm of overlapping sites of bone and articular cartilage of right limb
C40.82	Malignant neoplasm of overlapping sites of bone and articular cartilage of left limb
C40.90	Malignant neoplasm of unspecified bones and articular cartilage of unspecified limb
C40.91	Malignant neoplasm of unspecified bones and articular cartilage of right limb
C40.92	Malignant neoplasm of unspecified bones and articular cartilage of left limb
C41.0	Malignant neoplasm of bones of skull and face
C41.1	Malignant neoplasm of mandible
C41.2	Malignant neoplasm of vertebral column
C41.3	Malignant neoplasm of ribs, sternum, and clavicle
C41.4	Malignant neoplasm of pelvic bones, sacrum, and coccyx
C41.9	Malignant neoplasm of bone and articular cartilage, unspecified

Folate Deficiency Anemia: ICD-10-CM Diagnosis Coding¹⁴

ICD-10 Code	Descriptor
D52.0	Dietary folate deficiency anemia
D52.1	Drug-induced folate deficiency anemia
D52.8	Other folate deficiency anemias
D52.9	Folate deficiency anemia, unspecified

Poisoning by Antineoplastic and Immunosuppressive Drugs (Unintentional): ICD-10-CM Diagnosis Coding¹⁴

ICD-10 Code	Descriptor
T45.1X1A	Poisoning by antineoplastic and immunosuppressive drugs, accidental (unintentional), initial encounter
T45.1X1D	Poisoning by antineoplastic and immunosuppressive drugs, accidental (unintentional), subsequent encounter
T45.1X1S	Poisoning by antineoplastic and immunosuppressive drugs, accidental (unintentional), sequela

Adverse Effect of Antineoplastic and Immunosuppressive Drugs: ICD-10-CM Diagnosis Coding¹⁴

ICD-10 Code	Descriptor
T45.1X5A	Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter
T45.1X5D	Adverse effect of antineoplastic and immunosuppressive drugs, subsequent encounter
T45.1X5S	Adverse effect of antineoplastic and immunosuppressive drugs, sequela

Encounter for Chemotherapy: ICD-10-CM Diagnosis Coding¹⁴

ICD-10 Code	Descriptor
Z51.11	Encounter for antineoplastic chemotherapy

Long Term Use of Anti-Metabolites (includes 5-fluorouracil and methotrexate): ICD-10-CM Diagnosis Coding¹⁴

ICD-10 Code	Descriptor
Z79.631	Long term (current) use of antimetabolite agent

Sample UB-04 / CMS 1450 Claim Form^{3,11,12,14,15}

Form Locator (FL) 42

(Electronic Claim Form = Loop 2400, Segment Type SV201):

List the appropriate revenue code for the drug. Match the descriptor for VYKOURA™ injection to your revenue code, 0636.

Additionally, enter an appropriate revenue code for the administration service, such as 0260, IV Therapy - General or others based on the cost center where the service was performed.

FL 43

(NOT REQUIRED BY MEDICARE):

Enter the description of the procedure for the Revenue Code billed.

If required, submit the N4 indicator first, followed by the 11-digit NDC code. Then, report the NDC unit measurement code followed by the quantity.

The NDC unit measurement code for VYKOURA is ML for milliliters.

FL 44

(Electronic Claim Form = Loop 2400, SV202-2 (SV202-1=HC/HP)

Enter the appropriate HCPCS code: J0644, Injection, leucovorin calcium (avysa), 1 mg

For administration, enter the appropriate code or codes for intravenous administration. As an example, CPT Code 96367* is used for intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion. List in addition to the primary procedure, unless drug is used alone.

FL 42

FL 43

FL 44

1		2		3a. PRI. CRTL. # b. MED. RES. # 5 FED. TAX NO.		4. TYPE OF BILL	
8 PATIENT NAME				9 PATIENT ADDRESS			
10 BIRTHDATE	11 SEX	12 DATE		13 HR		14 TYPE	15 SPC
16 DHR		17 STAT		18		19	
20		21		22		23	
24		25		26		27	
28		29		30		31	
32		33		34		35	
36		37		38		39	
40		41		42		43	
44		45		46		47	
48		49		50		51	
52		53		54		55	
56		57		58		59	
60		61		62		63	
64		65		66		67	
68		69		70		71	
72		73		74		75	
76		77		78		79	
80		81		82		83	
84		85		86		87	
88		89		90		91	
92		93		94		95	
96		97		98		99	
100		101		102		103	
104		105		106		107	
108		109		110		111	
112		113		114		115	
116		117		118		119	
120		121		122		123	
124		125		126		127	
128		129		130		131	
132		133		134		135	
136		137		138		139	
140		141		142		143	
144		145		146		147	
148		149		150		151	
152		153		154		155	
156		157		158		159	
160		161		162		163	
164		165		166		167	
168		169		170		171	
172		173		174		175	
176		177		178		179	
180		181		182		183	
184		185		186		187	
188		189		190		191	
192		193		194		195	
196		197		198		199	
200		201		202		203	
204		205		206		207	
208		209		210		211	
212		213		214		215	
216		217		218		219	
220		221		222		223	
224		225		226		227	
228		229		230		231	
232		233		234		235	
236		237		238		239	
240		241		242		243	
244		245		246		247	
248		249		250		251	
252		253		254		255	
256		257		258		259	
260		261		262		263	
264		265		266		267	
268		269		270		271	
272		273		274		275	
276		277		278		279	
280		281		282		283	
284		285		286		287	
288		289		290		291	
292		293		294		295	
296		297		298		299	
300		301		302		303	
304		305		306		307	
308		309		310		311	
312		313		314		315	
316		317		318		319	
320		321		322		323	
324		325		326		327	
328		329		330		331	
332		333		334		335	
336		337		338		339	
340		341		342		343	
344		345		346		347	
348		349		350		351	
352		353		354		355	
356		357		358		359	
360		361		362		363	
364		365		366		367	
368		369		370		371	
372		373		374		375	
376		377		378		379	
380		381		382		383	
384		385		386		387	
388		389		390		391	
392		393		394		395	
396		397		398		399	
400		401		402		403	
404		405		406		407	
408		409		410		411	
412		413		414		415	
416		417		418		419	
420		421		422		423	
424		425		426		427	
428		429		430		431	
432		433		434		435	
436		437		438		439	
440		441		442		443	
444		445		446		447	
448		449		450		451	
452		453		454		455	
456		457		458		459	
460		461		462		463	
464		465		466		467	
468		469		470		471	
472		473		474		475	
476		477		478		479	
480		481		482		483	
484		485		486		487	
488		489		490		491	
492		493		494		495	
496		497		498		499	
500		501		502		503	
504		505		506		507	
508		509		510		511	
512		513		514		515	
516		517		518		519	
520		521		522		523	
524		525		526		527	
528		529		530		531	
532		533		534		535	
536		537		538		539	
540		541		542		543	
544		545		546		547	
548		549		550		551	
552		553		554		555	
556		557		558		559	
560		561		562		563	
564		565		566		567	
568		569		570		571	
572		573		574		575	
576		577		578		579	
580		581		582		583	
584		585		586		587	
588		589		590		591	
592		593		594		595	
596		597		598		599	
600		601		602		603	
604		605		606		607	
608		609		610		611	
612		613		614		615	
616		617		618		619	
620		621		622		623	
624		625		626		627	
628		629		630		631	
632		633		634		635	
636		637		638		639	
640		641		642		643	
644		645		646		647	
648		649		650		651	
652		653		654		655	
656		657		658		659	
660		661		662		663	
664		665		666		667	
668		669		670		671	
672		673		674		675	
676		677		678		679	
680		681		682		683	
684		685		686		687	
688		689		690		691	
692		693		694		695	
696		697		698		699	
700		701		702		703	
704		705		706		707	
708		709		710		711	
712		713		714		715	
716		717		718		719	
720		721		722		723	
724		725		726		727	
728		729		730		731	
732		733		734		735	
736		737		738		739	
740		741		742		743	
744		745		746		747	
748		749		750		751	
752		753		754		755	
756		757		758		759	
760		761		762		763	
764		765		766		767	
768		769		770		771	
772		773		774		775	
776		777		778		779	
780		781		782		783	
784		785		786		787	
788		789		790		791	
792		793		794		795	
796		797		798		799	
800		801		802		803	
804		805		806		807	
808		809		810		811	
812		813		814		815	
816		817		818		819	
820		821		822		823	
824		825		826		827	
828		829		830		831	
832		833		834		835	

FL 45

(Electronic Claim Form = Loop 2400, Segment DTP/472/03):

Enter the date of service.

FL 46

(Electronic Claim Form = Loop 2400, SV205):

Enter the units for the HCPCS code billed. Enter the number of service units for each item.

FL 63

(Electronic Claim Form = Loop 2300, REF/G/1/02):

Enter treatment authorization code.

FL 67A-Q

(Electronic Claim Form Loop 2300, H101-2 (H101-1=BK):

Enter a diagnosis code for the drug documented in the medical record. Be as specific as possible.

An example is: C40.02, Malignant neoplasm of scapula and long bones of left upper limb; and T45.1X5A, Adverse effect of antineoplastic and immunosuppressive drugs, initial encounter.

Electronic Claims Reference: ASC 837I Version 5010A2 Institutional Health Care Claim to the CMS-1450 Claim Form Crosswalk. Palmettogba. Com. Palmetto GBA, Accessed September 16, 2025. [https://www.palmettogba.com/pal-%20metto/providers.nsf/files/EDI_837I_v5010A2_crosswalk.pdf/\\$FILE/EDI_837I_v5010A2_crosswalk.pdf](https://www.palmettogba.com/pal-%20metto/providers.nsf/files/EDI_837I_v5010A2_crosswalk.pdf/$FILE/EDI_837I_v5010A2_crosswalk.pdf)

CPT Codes are a registered trademark of the American Medical Association (AMA), All Rights Reserved.

THIS INFORMATION IS PROVIDED FOR EDUCATIONAL PURPOSES ONLY AND IS NOT A GUARANTEE OF COVERAGE. IT IS THE SOLE RESPONSIBILITY OF THE HEALTH CARE PROVIDER TO SELECT THE PROPER CODES AND ENSURE THE ACCURACY OF ALL STATEMENTS USED IN SEEKING COVERAGE AND REIMBURSEMENT FOR AN INDIVIDUAL PATIENT.

Sample CMS 1500 Claim Form^{3,5,6,11,13,14}

Use Item 21 C-L fields for other secondary diagnoses.

Enter prior authorization number if one exists.

The NDC unit measurement code for VYKOURA™ is ML for milliliters.

HEALTH INSURANCE CLAIM FORM										CARRIER
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12										PICA
☐ MEDICARE ☐ MEDICAID ☐ TRICARE ☐ CHAMPVA ☐ GROUP HEALTH PLAN ☐ FECA BOX (LUNG) ☐ OTHER										PICA
1. INSURED'S ID NUMBER (For Program in Item 1)										
2. PATIENT'S NAME (Last Name, First Name, Middle Initial)										
3. PATIENT'S BIRTH DATE										
4. INSURED'S NAME (Last Name, First Name, Middle Initial)										
5. PATIENT'S ADDRESS (No., Street)										
6. PATIENT RELATIONSHIP TO INSURED										
7. INSURED'S ADDRESS (No., Street)										
8. RESERVED FOR NUCC USE										
9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)										
10. IS PATIENT'S CONDITION RELATED TO:										
11. INSURED'S POLICY GROUP OR FECA NUMBER										
a. OTHER INSURED'S POLICY OR GROUP NUMBER										
b. RESERVED FOR NUCC USE										
c. RESERVED FOR NUCC USE										
d. INSURANCE PLAN NAME OR PROGRAM NAME										
12. CLAIM CODES (Designated by NUCC)										
13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE (I authorize the release of any medical or other information necessary to process this claim. I also request payment of government benefits either to myself or to the party who accepts assignment below.)										
14. DATE OF CURRENT ILLNESS, INJURY, or PREGNANCY (LMP)										
15. OTHER DATE										
16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION										
17. NAME OF REFERRING PROVIDER OR OTHER SOURCE										
18. HOSPITALIZATION DATES RELATED TO CURRENT SERVICES										
19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)										
20. OUTSIDE LAB?										
21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY (Relate A-L to service line below (24B))										
22. RESUBMISSION CODE										
23. PRIOR AUTHORIZATION NUMBER										
24. A. DATE(S) OF SERVICE From To B. PLACE OF SERVICE C. D. PROCEDURES, SERVICES, OR SUPPLIES (Explain Unusual Circumstances) E. DIAGNOSIS F. CHARGES G. DAYS OF UNITS H. ICD-9-CM I. QUAL J. RENDERING PROVIDER ID. #										
25. FEDERAL TAX ID NUMBER SSN EIN										
26. PATIENT'S ACCOUNT NO										
27. ACCEPT ASSIGNMENT? (YES/NO)										
28. TOTAL CHARGE										
29. AMOUNT PAID										
30. Paid for NUCC Use										
31. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREES OR CREDENTIALS (I certify that the statements on the reverse apply to the bill and are made a part thereof.)										
32. SERVICE FACILITY LOCATION INFORMATION										
33. BILLING PROVIDER INFO & P#										
SIGNED DATE										

Item 24D

(Electronic Claim Form = Loop 2400, Segment SV101):

Enter the appropriate HCPCS code: J0644, Injection, leucovorin calcium (avyxa), 1 mg

For administration, enter the appropriate code or codes for intravenous administration. As an example, CPT Code 96367* is used for intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion. List in addition to the primary procedure, unless drug is used alone.

Item 24E

(Electronic Claim Form = Loop 2400, Segment SV107):

Specify the diagnosis letter that corresponds with the drug and drug administration code(s) in Item 21.

Item 24G

(Electronic Claim Form = Loop 2400, SV104):

Enter the number of J-Code service units for each item.



HEALTH INSURANCE CLAIM FORM
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE (NUCC) 02/12

☐ PICA ☐ PICA

1. MEDICARE ☐ MEDICAID ☐ TRICARE ☐ CHAMPVA ☐ GROUP HEALTH PLAN ☐ FECA (LUNG) ☐ OTHER ☐ (ID#) ☐ (ID#)

2. PATIENT'S NAME (Last Name, First Name, Middle Initial)

3. PATIENT'S BIRTH DATE MM DD YY SEX M ☐ F ☐

4. INSURED'S NAME (Last Name, First Name, Middle Initial)

5. PATIENT'S ADDRESS (No., Street)

6. PATIENT RELATIONSHIP TO INSURED Self ☐ Spouse ☐ Child ☐ Other ☐

7. INSURED'S ADDRESS (No., Street)

8. RESERVED FOR NUCC USE

9. OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)

10. IS PATIENT'S CONDITION RELATED TO:

11. INSURED'S POLICY GROUP OR FECA NUMBER

a. OTHER INSURED'S POLICY OR GROUP NUMBER

a. EMPLOYMENT? (Current or Previous) YES ☐ NO ☐

b. RESERVED FOR NUCC USE

b. AUTO ACCIDENT? YES ☐ NO ☐ PLACE (State)

c. RESERVED FOR NUCC USE

c. OTHER ACCIDENT? YES ☐ NO ☐

d. INSURANCE PLAN NAME OR PROGRAM NAME

10d. CLAIM CODES (Designated by NUCC)

13. INSURED'S OR AUTHORIZED PERSON'S SIGNATURE: I authorize the release of any medical or other information necessary to process this claim. I also request payment of government benefits either to myself or to the party who accepts assignment below.

14. DATE OF CURRENT ILLNESS, INJURY, OR PREGNANCY (UMP) MM DD YY

15. OTHER DATE QUAL MM DD YY

16. DATES PATIENT UNABLE TO WORK IN CURRENT OCCUPATION FROM MM DD YY TO MM DD YY

17. NAME OF REFERRING PROVIDER OR OTHER SOURCE

17a. NPI

18. HOSPITALIZATION DATES RELATED TO CURRENT SERVICES FROM MM DD YY TO MM DD YY

19. ADDITIONAL CLAIM INFORMATION (Designated by NUCC)

20. OUTSIDE LAB? YES ☐ NO ☐ \$ CHARGES

21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY: Relate A-L to service line below (24E) ICD Ind.

A. L. B. L. C. L. D. L. E. L. F. L. G. L. H. L. I. L. J. L. K. L. L. L.

22. RESUBMISSION CODE ORIGINAL REF. NO.

23. PRIOR AUTHORIZATION NUMBER

24. A. DATES OF SERVICE From MM DD YY To MM DD YY

24. B. PROCEDURES, SERVICES, OR SUPPLIES (CPT/HCPCS) (Explain Unusual Circumstances) MODIFIER

24. C. DIAGNOSIS POINTER

24. D. \$ CHARGES

24. E. DATES (MM DD YY) FROM TO

24. F. ID. QUAL

24. G. RENDERING PROVIDER ID. #

25. FEDERAL TAX I.D. NUMBER

26. PATIENT'S ACCOUNT NO.

27. ACCEPT ASSIGNMENT? YES ☐ NO ☐

28. TOTAL CHARGE \$

29. AMOUNT PAID \$

30. Paid for NUCC Use

31. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREES OR CREDENTIALS (I certify that the statements on the reverse apply to this bill and are made a part thereof)

32. SERVICE FACILITY LOCATION INFORMATION

33. BILLING PROVIDER INFO & PH# ()

SIGNED DATE

PLEASE PRINT OR TYPE

APPROVED CMB-0938-1197 FORM 1500 (02-12)

*CPT Code 96367 Intravenous infusion, for therapy, prophylaxis, or diagnosis (specify substance or drug); additional sequential infusion of a new drug/substance, up to 1 hour (List separately in addition to code for primary procedure).

Electronic Claims Reference: ASC 837I Version 5010A2 Institutional Health Care Claim to the CMS-1450 Claim Form Crosswalk. Palmettogba. Com. Palmetto GBA, Accessed September 16, 2025. [https://www.palmettogba.com/pal-%20metto/providers.nsf/files/EDI_837I_v5010A2_crosswalk.pdf/\\$FILE/EDI_837I_v5010A2_crosswalk.pdf](https://www.palmettogba.com/pal-%20metto/providers.nsf/files/EDI_837I_v5010A2_crosswalk.pdf/$FILE/EDI_837I_v5010A2_crosswalk.pdf)

CPT Codes are a registered trademark of the American Medical Association (AMA), All Rights Reserved.

THIS INFORMATION IS PROVIDED FOR EDUCATIONAL PURPOSES ONLY AND IS NOT A GUARANTEE OF COVERAGE. IT IS THE SOLE RESPONSIBILITY OF THE HEALTH CARE PROVIDER TO SELECT THE PROPER CODES AND ENSURE THE ACCURACY OF ALL STATEMENTS USED IN SEEKING COVERAGE AND REIMBURSEMENT FOR AN INDIVIDUAL PATIENT.

IMPORTANT SAFETY INFORMATION (CONTINUED)

DRUG INTERACTIONS

Effects of Other Drugs on VYKOURA

Glucarpidase

Administer VYKOURA at least 2 hours before or 2 hours after the glucarpidase dose when administering concomitantly. Glucarpidase can decrease leucovorin concentrations, which may decrease the effect of leucovorin rescue.

Effects of VYKOURA on Other Drugs

Certain Antiepileptic Drugs

Increase monitoring for seizure activity in patients taking certain concomitant antiepileptic drugs.

Folic acid in high doses may reduce the effectiveness of certain antiepileptic drugs (e.g., phenobarbital, phenytoin, and primidone) and thereby increase the frequency of seizures.

Trimethoprim-Sulfamethoxazole

Avoid concomitant use of VYKOURA with trimethoprim-sulfamethoxazole. The effectiveness of trimethoprim-sulfamethoxazole can be decreased if used concomitantly with VYKOURA which was associated with increased rates of treatment failure and mortality in patients with HIV infection who receive trimethoprim-sulfamethoxazole for the acute treatment of *Pneumocystis jirovecii* pneumonia.

USE IN SPECIFIC POPULATIONS

Pregnancy

Agents administered in combination with VYKOURA may cause fetal harm. Refer to the Prescribing Information for agents administered in combination with VYKOURA for additional information.

Lactation

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for VYKOURA and any potential adverse effects on the breastfed infant from VYKOURA or from the underlying maternal condition.

Refer to the Prescribing Information for agents administered in combination with VYKOURA for breastfeeding recommendations.

Pediatric Use

VYKOURA is indicated to reduce the toxicity of MTX in pediatric patients with impaired MTX elimination, and folic acid antagonists or dihydrofolate reductase (DHFR) inhibitors following an overdose.

Geriatric Use

Clinical studies of leucovorin calcium did not show differences in safety or effectiveness between subjects over 65 and younger subjects. Other clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older patients cannot be ruled out. This drug is known to be excreted by the kidney and the risk of toxic reactions to the drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection in this patient population.

IMPORTANT SAFETY INFORMATION (CONTINUED)

DOSAGE AND ADMINISTRATION GUIDELINES

- VYKOURA is indicated for intravenous (IV) and intramuscular (IM) administration. **Do not administer intrathecally. VYKOURA may be harmful or fatal if given intrathecally.**
- Do NOT mix VYKOURA with other drugs or administer other drugs through the same intravenous line. A precipitate may form if VYKOURA is mixed with fluorouracil.
- Due to the calcium content of VYKOURA, do **NOT** exceed the maximum infusion rate of 160 mg/minute to avoid hypercalcemia.

Please see full Prescribing Information of VYKOURA.

To report SUSPECTED ADVERSE REACTIONS, contact AVYXA Pharma, LLC at 1-888-520-0954 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

This image shows a single sheet of white paper with horizontal ruling lines. The lines are evenly spaced and run across the width of the page. There are no margins, text, or other markings on the paper.

VYKOURA™ (leucovorin calcium) injection offers resources to help your patients start and stay on prescribed therapy.

We are dedicated to providing your patients with ongoing support to help them access AVYXA medications as prescribed.



Contact your Account Manager to connect with a Field Reimbursement Manager for the latest payer coverage for patients and assistance with billing and coding.

References: 1. VYKOURA Prescribing Information. AVYX Pharma, LLC. Revised January 2026. 2. Drugs.com. National drug codes explained. Accessed August 19, 2025. <https://www.drugs.com/ndc.html#:~:text=The%20CMS%20NDC%20identifier%20is,5%2D4%2D2%20configuration> 3. American Academy of Professional Coders (AAPC). HCPCS Level II Expert: Service/Supply Codes for Caregivers & Suppliers 2025. AAPC; 2024. 4. Centers for Medicare & Medicaid Services. Healthcare Common Procedure Coding System (HCPCS) Application Summaries and Coding Determinations: Second Quarter, 2026 HCPCS Coding Cycle. 2026. 5. Florida Medical Association. Article - billing and coding: complex drug administration coding (A59074). Accessed August 22, 2025. https://www.flmedical.org/florida/Florida_Public/Docs/LCA-A59074.pdf 6. Centers for Medicare and Medicaid Services. Medicare claims processing manual: chapter 26 – completing and processing the form CMS 1500 data set. Transmittal 10 – health insurance claim form CMS 1500. Accessed August 21, 2025. <https://www.cms.gov/regulations-and-guidance/guidance/manuals/downloads/clm104c26pdf.pdf> 7. American Academy of Professional Coders (AAPC). What Are Medical Coding Modifiers? Accessed November 3, 2025. <https://www.aapc.com/resources/what-are-medical-coding-modifiers?srsId=AfmBOopepZVWxPdYt5ymJbYKZW5YxQqYM580D5a8rLdRklw3jnLvD> 8. Centers for Medicare and Medicaid Services. Billing and coding: JW and JZ modifier billing guidelines. Accessed September 3, 2025. <https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleid=55932> 9. Centers for Medicare and Medicaid Services. Medicare Part B Inflation Rebate Guidance: Use of the 340B Modifier. Accessed November 3, 2025. <https://www.cms.gov/files/document/mln4800856-medicare-part-b-inflation-rebate-guidance-use-340b-modifier.pdf> 10. American Medical Association. CPT® overview and code approval. Accessed August 19, 2025. <https://www.ama-assn.org/practice-management/cpt/cpt-code-set-overview> 11. American Medical Association. Current Procedural Terminology: CPT 2025 Professional Edition. AMA; 2024. 12. Noridian Healthcare Solutions. Revenue codes. Accessed August 21, 2025. <https://med.noridianmedicare.com/web/jfa/topics/claim-submission/revenue-codes> 13. Centers for Medicare and Medicaid Services. Place of service code set. Accessed August 20, 2025. <https://www.cms.gov/medicare/coding-billing/place-of-service-codes/code-sets> 14. American Academy of Professional Coders (AAPC). ICD-10-CM Expert: Diagnosis codes for providers & facilities 2025. AAPC; 2024. 15. Centers for Medicare and Medicaid Services. Medicare claims processing manual: chapter 25 – completing and processing the form CMS 1450 data set. Transmittal 75- general instructions for completion of form CMS1450 for billing. Accessed August 19, 2025. <https://www.cms.gov/regulations-and-guidance/guidance/manuals/downloads/clm104c25.pdf>